
The $2.5 Billion Question in Pharmaceutical Antitrust
In this episode, we examine the economic foundations of reverse-payment antitrust law through the lens of the Takeda verdict. The Supreme Court’s *Actavis* decision shifted the focus from patent validity to payment size—
Show notes

























